8-K: RAPT Therapeutics Completes 1-for-8 Reverse Stock Split to Consolidate Shares

RAPT Therapeutics, Inc. has officially implemented a 1-for-8 reverse stock split of its common stock, effective June 16, 2025, following stockholder approval.

Summary

• RAPT Therapeutics, Inc. (the "Company") has effected a 1-for-8 reverse stock split of its common stock, $0.0001 par value per share.
• The reverse stock split became effective on June 16, 2025, at 11:59 p.m. Eastern Time.
• The Company's stockholders approved the amendment to the Amended and Restated Certificate of Incorporation to enable the reverse stock split on May 29, 2025.
• A Certificate of Amendment was filed with the Secretary of State of the State of Delaware on June 13, 2025.
• Immediately after the split's effectiveness (and proportionate share capital reduction, but prior to eliminating fractional shares), approximately 16.5 million shares of common stock were issued and outstanding.
• No fractional shares will be issued as a result of the split; instead, holders of fractional shares will receive a cash payment equal to the fraction multiplied by the closing sales price of the common stock immediately preceding the effective time.
• The reverse stock split is applied on a record holder-by-record holder basis, aggregating any fractional shares held by a single record holder.
• The par value of each common stock share remains $0.0001 after the split.
• The Company's Amended and Restated Certificate of Incorporation now authorizes a total of 550,000,000 shares, consisting of 500,000,000 common stock shares and 50,000,000 preferred stock shares.

Sentiment

Score: 5

Explanation: The document reports a procedural corporate action (reverse stock split) that was previously approved by stockholders. While such actions are often taken to meet listing requirements or improve stock perception, the filing itself is neutral in tone and simply reports the completion of the action without providing new financial performance data or strategic updates.

Negatives

• Reverse stock splits are often perceived negatively by investors as they can signal underlying issues with a company's stock price performance, such as a low share price potentially below exchange minimums.
• While the per-share price is expected to increase proportionally, the action itself does not change the company's fundamental value or market capitalization, and can sometimes be followed by further stock price declines.

Future Outlook

NA

Management Comments

• "RAPT Therapeutics, Inc. has caused this Certificate of Amendment to be signed by its Chief Executive Officer on this 13th day of June, 2025." (Signed by Brian Wong, President and Chief Executive Officer)
• "Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized." (Signed by Rodney Young, Chief Financial Officer)

Industry Context

Reverse stock splits are a common corporate action undertaken by companies whose stock price has fallen significantly, often to meet minimum bid price requirements of major exchanges like Nasdaq. This action aims to increase the per-share price, potentially improving market perception, liquidity, and attracting a broader range of investors, although it does not alter the company's underlying valuation or business fundamentals.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience a reduction in the number of shares they hold by a factor of eight, with the per-share price theoretically increasing proportionally. Holders of fractional shares will receive cash payments instead of new shares.
• Nasdaq Stock Market: The reverse stock split may help the Company maintain compliance with Nasdaq's listing requirements, particularly minimum bid price rules, by increasing the per-share trading price.

Next Steps

• The Company will proceed with the payment of cash in lieu of fractional shares to eligible holders resulting from the reverse stock split.

Key Dates

Keywords

RAPT Therapeutics, reverse stock split, common stock, share consolidation, Nasdaq, 8-K filing, corporate action, equity, stock market